Referral Status: 🛘 New Patient 📮 Updated Patient Informa	Referral Status:
--	------------------



## **CMC Infusion Center- Referral Face Sheet**

Patient Name:	Patient D.O.B				
Current Height:	Current Weight				
Patient Phone # ()	Gender				
Patient Address					
CityState _	Zip Code				
Related Diagnosis Code (ICD-10 code):					
Referring Provider (Please Print)					
Office Phone # ()	Office Contact:				

## If referring provider and/or patient is external to Conway Medical Center. Please include:

- Most recent history and physical including:
  - o Comprehensive medication list
  - o Past medical history
  - Related past/ failed therapies (with dates)
  - Known allergies
- Most recent labs / test result (Ex. CBC, PPD, Hepatitis screening, etc.)
- Insurance Information

Please fax requested documentation, face sheet, and treatment plan to **843-234-5460** attention CMC Medication Management Specialist. Please feel free to call 843-234-8575 with any questions.

We look forward to the opportunity to be a part of your patient's treatment journey at Conway Medical Center.



## Entyvio® (vedolizumab) Treatment Plan

Patient Name: Patient DOB				
General  Diagnosis- Crohn's Disease ICD-10 Code Diagnosis- Ulcerative Colitis ICD-10 Code				
Pt. Weight Pt Height Known Allergies				
Requested Start Date/				
Has patient previously received this medication $\square$ No $\square$ Yes, if so, date of last infusion/				
Authorized Treatment Duration  Loading Dose:  Infuse on day 1, week 2, week 6, then every 8 weeks x 12 months  Maintenance Dose:  Every 8 weeks x 12 months				
Infusion Monitoring  Vital Signs  every 30 min, Prior to infusion, every 30 minutes during infusion, and prior to discharge  Pre-Medications - Administer 30 minutes before vedolizumab dose if required				
Pre-Medications				
Tylenol  650 mg, Oral, Tab, Day of Tx  Comments: Administer 30 minutes before vedolizumab dose				
Benadryl  25 mg, IV Push, Injection, Day of Tx				
Comments: Administer 30 minutes before vedolizumab dose  50 mg, IV Push, Injection, Day of Tx  Comments: Administer 30 minutes before vedolizumab dose				
SOLU-Medrol				
40 mg, IV Push, Powder-Inj, Day of Tx Comments: Administer 30 minutes before vedolizumab dose				
☐ 125 mg, IV Push, Powder-Inj, Day of Tx Comments: Administer 30 minutes before vedolizumab dose				
Entyvio  300 mg, IV Piggyback, Powder-Inj, Comments: in 250 mL Ns over 30 minutes. Following infusion, flush with 30 mL of sterile 0.9% sodium chloride injection. Monitor for hypersensitivity reactions				
Communication Order  Patient must stay in infusion area for 30 min post infusion. If vital signs normal may be discharged to home. If abnormal, call physician				
Prescriber Signature (No Stamped Signatures or Electronic Signatures)				
Provider Signature Provider Name (please print)				
Data / / Detiont Name Potiont DOP				

## Entyvio® (vedolizumab) Treatment Plan

	Biosimilar Substitu	ition <b>NOT</b> permitted			
Date_	//	Patient Name	Patient DOB		
Provi	der Signature _		Provider Name (please print)		
Pres	criber Signatur	e (No Stamped Signatu	res or Electronic Signatures)		
		·			
Labs ☑	( <b>Days 0, 14, 28)</b> QuantiFERON	Duration: 12 months  N TB Gold Plus (if needed)			
		Comments: To maintain cer deaccess	ntral line patency for implanted ports, flush once monthly or prior to		
	heparin flush 10	0 units/mL intravenous solu ntracatheter, Injection, Once	tion (Day 0, 14, 28) , <i>PRN other (see comment)</i>		
$\overline{\mathbf{v}}$	<i>last 12 l</i> INF Infusion Ro	<i>months</i> om Orders Subphase (Day (	0, 14, 28)		
Notify Provider  For POSITIVE results of PPD test or oth			ther test to exclude latent tuberculosis. Results must be within the		
_	for Feve	er/Chills, chest pain, hypoter eature > 100 or HR <50 or >	nsion, hypertension, dyspnea, pruritis, urticarial, persistent flushing, 130		
v		Results must be from the la			
$\Box$	Communication Order Obtain results of PPD test or other test to exclude latent tuberculosis if results not present in medical				